Glenmark receives ANDA nod for Dimethyl Fumarate Delayed-Release Capsules

Glenmark receives ANDA nod for Dimethyl Fumarate Delayed-Release Capsules

by admin- Wednesday, October 7th, 2020 04:02:46 PM

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted very last approval with the aid of the United States Food & Drug Administration (USFDA) for Dimethyl Fumarate
Delayed-Release Capsules, a hundred and twenty mg and 240 mg, the regular version of Tecfidera1 Delayed-Release Capsules, 120 mg and 240 mg, of Biogen, Inc.

News Updates